Afrisham et al. demonstrated increased serum CCN3 levels in MASLD patients, which correlated with elevated interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), compared to healthy controls [43,44]. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.